DM
Deerfield Management Portfolio holdings
AUM
$5.51B
1-Year Return
12.76%
This Quarter Return
+21.45%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.75B
AUM Growth
+$332M
(+6.1%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-14.52%
Top 10 Holdings %
Top 10 Hldgs %
51.71%
Holding
447
New
223
Increased
65
Reduced
45
Closed
77
Top Buys
| 1 |
BioNTech
BNTX
|
$52.5M |
| 2 |
Kyverna Therapeutics
KYTX
|
$36.3M |
| 3 |
Perspective Therapeutics
CATX
|
$33.5M |
| 4 |
Larimar Therapeutics
LRMR
|
$32.6M |
| 5 |
Surgery Partners
SGRY
|
$32.3M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
$66.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$64M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$62.6M |
| 4 |
Baxter International
BAX
|
$57.8M |
| 5 |
Neurocrine Biosciences
NBIX
|
$28.4M |
Sector Composition
| 1 | Healthcare | 88.87% |
| 2 | Industrials | 0.71% |
| 3 | Technology | 0.31% |
| 4 | Consumer Discretionary | 0.26% |
| 5 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Maximus
MMS
$5.03B
| $206K | ﹤0.01% |
2,452
-2,825
| -54% | -$237K |
|
327
Aris Water Solutions
ARIS
$781M
| $204K | ﹤0.01% |
14,400
-10,154
| -41% | -$144K |
|
|
JWN
328
DELISTED
Nordstrom
JWN
| $202K | ﹤0.01% |
+9,971
| New | +$202K |
|
329
Keurig Dr Pepper
KDP
$39.6B
| $200K | ﹤0.01% |
+6,531
| New | +$200K |
|
330
Hain Celestial
HAIN
$172M
| $199K | ﹤0.01% |
+25,343
| New | +$199K |
|
331
Amicus Therapeutics
FOLD
$2.51B
| $194K | ﹤0.01% |
+16,489
| New | +$194K |
|
332
Sunrun
RUN
$4.05B
| $189K | ﹤0.01% |
+14,319
| New | +$189K |
|
333
Pulmonx
LUNG
$71.7M
| $188K | ﹤0.01% |
+20,289
| New | +$188K |
|
334
KalVista Pharmaceuticals
KALV
$775M
| $182K | ﹤0.01% |
+15,353
| New | +$182K |
|
335
Innodata
INOD
$1.34B
| $180K | ﹤0.01% |
+27,305
| New | +$180K |
|
336
OraSure Technologies
OSUR
$238M
| $177K | ﹤0.01% |
28,755
+7,116
| +33% | +$43.8K |
|
|
NVRO
337
DELISTED
NEVRO CORP.
NVRO
| $175K | ﹤0.01% |
+12,135
| New | +$175K |
|
338
Hims & Hers Health
HIMS
$10.9B
| $163K | ﹤0.01% |
10,521
-4,910
| -32% | -$76K |
|
339
Xeris Biopharma Holdings
XERS
$1.26B
| $163K | ﹤0.01% |
+73,570
| New | +$163K |
|
340
MBIA
MBI
$395M
| $161K | ﹤0.01% |
+23,856
| New | +$161K |
|
341
Phibro Animal Health
PAHC
$1.58B
| $161K | ﹤0.01% |
+12,433
| New | +$161K |
|
342
Terns Pharmaceuticals
TERN
$616M
| $158K | ﹤0.01% |
24,060
+6,770
| +39% | +$44.4K |
|
|
VERV
343
DELISTED
Verve Therapeutics
VERV
| $153K | ﹤0.01% |
+11,504
| New | +$153K |
|
344
Alphatec Holdings
ATEC
$2.44B
| $140K | ﹤0.01% |
+10,136
| New | +$140K |
|
345
Weave Communications
WEAV
$598M
| $138K | ﹤0.01% |
11,989
+1,249
| +12% | +$14.3K |
|
346
Berry Corp
BRY
$254M
| $118K | ﹤0.01% |
+14,689
| New | +$118K |
|
347
Cerus
CERS
$253M
| $113K | ﹤0.01% |
+59,637
| New | +$113K |
|
348
Sabre
SABR
$683M
| $111K | ﹤0.01% |
+45,982
| New | +$111K |
|
349
Health Catalyst
HCAT
$240M
| $111K | ﹤0.01% |
+14,713
| New | +$111K |
|
350
Sutro Biopharma
STRO
$91.6M
| $95.6K | ﹤0.01% |
+16,925
| New | +$95.6K |
|